CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the genetic basis of drug resistance in malignant melanoma. By analyzing early-passage melanoma cell cultures, it aims to identify resistance genes and develop combination therapies that can effectively target these mechanisms to improve treatment outcomes.
Malignant melanoma is a highly aggressive form of skin cancer with a poor outcome following metastatic spread.
Chemotherapies for metastatic melanoma are rarely curative because of the emergence of clones from within the tumor that carry lesions in genes that confer therapeutic resistance.
Understanding the genetic culprits of drug resistance will allow the rationale development of combination therapies that may circumvent the occurrence of resistance.Here I propose to combine different cutting-…
GENOME RESEARCH LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
